DJIA 17,826.30 -279.47 -1.54%
NASDAQ 4,931.82 -75.98 -1.52%
S&P 500 2,081.18 -23.81 -1.13%
market minute promo

Acorda Therapeutics, Inc. (NASDAQ: ACOR)

34.49 -0.19 (-0.55%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ACOR $34.49 -0.55%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $34.50
Previous Close $34.68
Daily Range $33.71 - $34.88
52-Week Range $28.26 - $45.45
Market Cap $1.5B
P/E Ratio 82.57
Dividend (Yield) $0.00 (0.0%)
Volume 623,511
Average Daily Volume 586,401
Current FY EPS -$0.10

Sector

Healthcare

Industry

Drug Makers

Acorda Therapeutics, Inc. (ACOR) Description

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS. Website: http://www.acorda.com/

News & Commentary Rss Feed

Forget MannKind Corporation; Here Are 3 Better Biotech Stocks

Although MannKind is launching Afrezza this year, our Motley Fool experts think these three stocks may be better buys.

Acorda Therapeutics (ACOR) Shares Cross Above 200 DMA

Alexion Up as Soliris Gains EU Nod for Label Updates - Analyst Blog

Adamas Pharma's Lead Candidate Gets Orphan Status in U.S. - Analyst Blog

Ocular Therapeutix Slumps 19% after Negative Study Data - Analyst Blog

Hospira Slammed with Another Warning Letter by the FDA - Analyst Blog

Alkermes Reports Encouraging Data on Schizophrenia Drug - Analyst Blog

Repros Gets EU Update on Secondary Hypogonadism Drug - Analyst Blog

Repros Gets EU Update on Secondary Hypogonadism Drug - Analyst Blog

Teva, Xenon Start Phase II Postherpetic Neuralgia Study - Analyst Blog

Teva, Xenon Start Phase II Postherpetic Neuralgia Study - Analyst Blog

Repros' Secondary Hypogonadism Drug Under FDA Review - Analyst Blog

Repros' Secondary Hypogonadism Drug Under FDA Review - Analyst Blog

Shire - Kyle Bass's 2nd Target

See More ACOR News...

ACOR's Top Competitors

ACOR $34.49 (-0.55%)
Current stock: ACOR
AMGN $163.58 (-1.97%)
Current stock: AMGN
GILD $101.38 (-1.90%)
Current stock: GILD
BIIB $419.44 (-2.15%)
Current stock: BIIB